What is the clinical evidence from this study?

Population: Genetic hypertension development (n=120). Intervention: Captopril and Dihydralazine vs. Distilled water. Primary outcome: Mean blood pressure (MBP) at 20 weeks of age (p=<0.001).

What question did this study set out to answer?

To compare the vascular and myocardial effects of captopril and dihydralazine during and following the development of genetic hypertension in young spontaneously hypertensive rats.

November 1, 1983British Journal of PharmacologyOpen Access

Compared myocardial and vascular effects of captopril and dihydralazine during hypertension development in spontaneously hypertensive rats

Q: What are the key findings of this study?

Captopril and dihydralazine both prevented genetic hypertension development in spontaneously hypertensive rats, reducing mean blood pressure to 117 mmHg compared to 160 mmHg in controls.

Q: What question did this study set out to answer?

To compare the vascular and myocardial effects of captopril and dihydralazine during and following the development of genetic hypertension in young spontaneously hypertensive rats.

View Full Paper

Ask AI

Bookmark

Key result

Captopril and dihydralazine both prevented genetic hypertension development in spontaneously hypertensive rats, reducing mean blood pressure to 117 mmHg compared to 160 mmHg in controls.

Why the study?

Does captopril or dihydralazine prevent functional and morphological vascular alterations during genetic hypertension development in spontaneously hypertensive rats?

Key Points

To compare the vascular and myocardial effects of captopril and dihydralazine during and following the development of genetic hypertension in young spontaneously hypertensive rats.
Treated young spontaneously hypertensive rats daily with either dihydralazine (25 mg kg-1) or captopril (100 mg kg-1) during genetic hypertension development.
Evaluated mesenteric vessel stiffness, vascular contractility, wall-to-lumen (W/L) ratio, and blood pressure both during therapy and up to 7 weeks following treatment withdrawal.
Dihydralazine reduced vessel stiffness by 27%, contractility by 12%, and W/L ratio by 15%, but all vascular parameters and blood pressure returned to control values within 7 weeks post-withdrawal.
Captopril decreased vessel stiffness by 16%, contractility by 15%, and W/L ratio by 30%, with both vascular structural improvements and blood pressure reductions persisting up to 7 weeks after treatment cessation.

Structured PICO

Does captopril or dihydralazine prevent functional and morphological vascular alterations during genetic hypertension development in spontaneously hypertensive rats?

Population

Young spontaneously hypertensive rats (SHRs)

Intervention

Captopril (100 mg kg-1, daily)

Comparator

Dihydralazine (25 mg kg-1, daily) and control

Outcome

Vascular mesenteric compliance, vessel stiffness, contractility, wall to lumen (W/L) ratio, and blood pressuresurrogate

Main Result

Absolute Event Rate: 117% vs 160%

p-value: p=<0.001

Captopril, unlike dihydralazine, exerts long-lasting protective effects on vascular structure and function in spontaneously hypertensive rats even after treatment is stopped.

Limitations

Animal model (spontaneously hypertensive rats) which may not fully translate to human hypertension

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Captopril may confer lasting vascular protection beyond BP reduction in rat models; leaves open human translation.

Cite This Study

Freslon et al. (1983) studied Genetic hypertension development (n=120). Captopril and Dihydralazine vs. Distilled water was evaluated on Mean blood pressure (MBP) at 20 weeks of age (p=<0.001). Captopril and dihydralazine both prevented genetic hypertension development in spontaneously hypertensive rats, reducing mean blood pressure to 117 mmHg compared to 160 mmHg in controls.

synapsesocial.com/papers/6a0f347ff7e1df59726c9824 https://doi.org/10.1111/j.1476-5381.1983.tb10726.x

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Compared myocardial and vascular effects of captopril and dihydralazine during hypertension development in spontaneously hypertensive rats

Key Points

Structured PICO

Main Result

Limitations

Discussion

Implication

Cite This Study

Topics

Compared myocardial and vascular effects of captopril and dihydralazine during hypertension development in spontaneously hypertensive rats

Key Points

Structured PICO

Main Result

Limitations

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider